Drug intelligence / Profile preview

APG-2575 + ibrutinib

Development stage: Unknown
Lead developer: Ascentage Pharma
Modality: Small Molecules
Administration: Oral

Overview

APG-2575 + ibrutinib is an investigational oral combination therapy for B-cell malignancies, especially chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and Waldenström macroglobulinemia (WM). APG-2575, also known as lisaftoclax, is a highly selective and potent BCL-2 inhibitor that induces apoptosis in malignant B cells. Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that blocks B-cell receptor signaling and impairs malignant cell survival. This regimen is being tested for synergistic anti-tumor activity, with clinical trials showing promising safety and efficacy in relapsed/refractory and treatment-naïve populations[1][3][4][5][6].

Brand names: lisaftoclax
Other names: lisaftoclax + ibrutinib

Targets

BCL-2 (BCL-2 family)BTK (Bruton tyrosine kinase)

Beyond the preview

Go deeper on APG-2575 + ibrutinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APG-2575 + ibrutinib.

Explore the full profile